Two financing approaches surfaced as potential solutions to the high capital demands of advanced therapies: a major spinout and an academic analysis of securitization. A new company, Atrium Therapeutics, launched with roughly $270 million in cash to continue RNA delivery programs for rare genetic cardiomyopathies spun out from Avidity’s assets; Atrium plans IND filings for two lead candidates this year. Separately, researchers modeled how securitization structures could underwrite the upfront costs of cell and gene therapies for orphan diseases, proposing pooled, outcome‑linked bonds as a way to spread risk and expand patient access. Together the moves highlight both private capital—spinouts backed by large balance sheets—and structured finance as complementary routes to scale curative modalities beyond single‑asset, single‑payer constraints.